506 related articles for article (PubMed ID: 30104294)
1. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J; Cheng A; Ritzel R; Bosnyak Z; Devisme C; Cali AMG; Sieber J; Stella P; Wang X; Frías JP; Roussel R; Bolli GB
Diabetes Care; 2018 Oct; 41(10):2147-2154. PubMed ID: 30104294
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
[TBL] [Abstract][Full Text] [Related]
3. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
[TBL] [Abstract][Full Text] [Related]
4. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
[TBL] [Abstract][Full Text] [Related]
5. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
6. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Cheng A; Harris S; Giorgino F; Seufert J; Ritzel R; Khunti K; Lauand F; Melas-Melt L; Westerbacka J; Bosnyak Z; Rosenstock J
Diabetes Obes Metab; 2020 Mar; 22(3):346-354. PubMed ID: 31646724
[TBL] [Abstract][Full Text] [Related]
7. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.
Ritzel R; Harris SB; Baron H; Florez H; Roussel R; Espinasse M; Muehlen-Bartmer I; Zhang N; Bertolini M; Brulle-Wohlhueter C; Munshi M; Bolli GB
Diabetes Care; 2018 Aug; 41(8):1672-1680. PubMed ID: 29895556
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
Danne T; Tamborlane WV; Malievsky OA; Franco DR; Kawamura T; Demissie M; Niemoeller E; Goyeau H; Wardecki M; Battelino T
Diabetes Care; 2020 Jul; 43(7):1512-1519. PubMed ID: 32430458
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
11. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
12. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
[TBL] [Abstract][Full Text] [Related]
13. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Haluzík M; Cheng A; Müller-Wieland D; Westerbacka J; Bosnyak Z; Lauand F; Melas-Melt L; Karalliedde J; Rosenstock J; Bolli GB
Diabetes Obes Metab; 2020 Aug; 22(8):1369-1377. PubMed ID: 32243043
[TBL] [Abstract][Full Text] [Related]
14. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
15. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
16. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
Sullivan SD; Nicholls CJ; Gupta RA; Menon AA; Wu J; Westerbacka J; Bosnyak Z; Frias JP; Bailey TS
Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
18. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
[TBL] [Abstract][Full Text] [Related]
19. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J; Diamant M; Aroda VR; Silvestre L; Souhami E; Zhou T; Perfetti R; Fonseca V;
Diabetes Care; 2016 Sep; 39(9):1579-86. PubMed ID: 27284114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
